Removing Prior Authorization Can Increase Access to Opioid Use TreatmentsJuly 3rd 2022
The removal of prior authorizations for buprenorphine for use in opioid use disorder was associated with a statistically significant increase in the number of prescriptions filled among Medicaid populations in Illinois but not in California, which had already been seeing an increase in use of such therapies.
Study: The Cost-effectiveness of Polivy Depends on OutcomesJune 20th 2022
A study in the journal Blood has found that the cost-effectiveness of the Polivy treatment regimen used to treat patients with diffuse large B-cell lymphoma would decrease if the five-year progression-free survival decreased.
PBM Exclusions Increasing, Finds New AnalysisJune 7th 2022
Xcenda’s review of the three largest PBMs—CVS Caremark, Express Scripts, and OptumRx—finds they are excluding medicines in classes where generics are not available or for serious conditions, such as oncology and autoimmune disorders.